Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Detalle, Laurent, Stohr, Thomas, Palomo, Concepción, Piedra, Pedro A., Gilbert, Brian E., Mas, Vicente, Millar, Andrena, Power, Ultan F., Stortelers, Catelijne, Allosery, Koen, Melero, José A., Depla, Erik
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2015
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704182/
https://ncbi.nlm.nih.gov/pubmed/26438495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01802-15
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares